Education
About Us
Working with TipRanks
Follow Us
Q-linea AB (DE:3F80)
:3F80
3F80 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.04 - €50.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)32.00
Market Cap
€29.25M
Enterprise Value€254.53M
Total Cash (Recent Filing)€82.71M
Total Debt (Recent Filing)€49.20M
Price to Earnings (P/E)―
Beta84.52
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,436,873
10 Day Avg. Volume40
30 Day Avg. Volume32
Financial Highlights & Ratios
PEG Ratio28.47
Price to Book (P/B)-20.81K
Price to Sales (P/S)241908.43
P/FCF Ratio-3.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Q-linea AB News
3F80 FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was €2.04 and its highest was €50.00 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is €29.25M.
When is Q-linea AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Q-linea AB’s earnings last quarter?
Currently, no data Available
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 6,436,873 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in DE:3F80
Company Description
Q-linea AB
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Q-linea AB (3F80) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
SciBase Holding AB
―
Clinical Laserthermia Systems AB Class B
―
SpectraCure AB
―
Luxbright AB
―
Acarix AB
―